Management of bullous pemphigoid (BP) consists of general skin care measures as well as
pharmacologic therapy and is aimed at attenuating autoantibody inflammation to promote …

Introduction: Bullous pemphigoid (BP) is the most common autoimmune subepidermal
blistering disease of the skin and mucosae. BP typically affects the elderly and manifests …

INTRODUCTION—Bullous pemphigoid is an autoimmune cutaneous blistering disease
characterized by autoantibody deposition at the epithelial basement membrane zone. The …

Bullous pemphigoid is the most common cutaneous autoimmune blistering diseases with an
estimated incidence in the United States of 24 cases per million person-years. It is a chronic …

Bullous pemphigoid is an autoimmune skin blistering disorder that can present with several
different degrees of severity. The treatment modality employed by the treating physician …

Bullous pemphigoid (BP) is the most frequently occurring autoimmune blistering disease in
Europe and North America. Although it is primarily a disease of the elderly, children and …

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease
in Western countries, and typically affects the elderly. BP is immunologically characterized …

In 1953, Lever differentiated bullous pemphigoid from autoimmune pemphigus. The natural
course of bullous pemphigoid is relatively benign, with a disease-related mortality rate of …

Bullous pemphigoid (BP) is a chronic, autoimmune, blistering disease observed primarily in
the elderly population. Several clinical variants have been described, including classic …

Bullous pemphigoid, the most common bullous autoimmune disorder of the skin, is primarily
a disease of the elderly. It is characterized by autoantibodies that target two structural …